Take a deep breath: Asthma drug study failed to include Black and Puerto Rican children who could benefit most

If a drug maker tested an asthma treatment in children and found it significantly reduced attacks compared with a placebo, this would be considered good news, yes?

But what if the children enrolled in the clinical trial were almost entirely white, even though asthma disproportionately affects Black and Puerto Rican children?

This would dampen my enthusiasm, to say the least. And it would make me wonder why a company would fail to study enough of the children who are most in need.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $399/year

$30 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In